1. Home
  2. MERC vs CALC Comparison

MERC vs CALC Comparison

Compare MERC & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

N/A

Current Price

$0.25

Market Cap

8.5M

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

N/A

Current Price

$1.35

Market Cap

7.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MERC
CALC
Founded
1968
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
7.6M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
MERC
CALC
Price
$0.25
$1.35
Analyst Decision
Sell
Buy
Analyst Count
2
4
Target Price
$0.13
★ $38.00
AVG Volume (30 Days)
★ 25.4M
78.7K
Earning Date
11-05-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $1,169,145,000.00
N/A
Revenue This Year
$0.85
N/A
Revenue Next Year
$11.46
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 25.50
N/A
52 Week Low
$0.12
$0.44
52 Week High
$2.85
$72.00

Technical Indicators

Market Signals
Indicator
MERC
CALC
Relative Strength Index (RSI) 56.93 44.38
Support Level $0.14 $1.00
Resistance Level $0.41 $1.84
Average True Range (ATR) 0.04 0.21
MACD 0.02 0.06
Stochastic Oscillator 52.79 40.24

Price Performance

Historical Comparison
MERC
CALC

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: